Zahraa Amer Hashim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zahraa Amer Hashim has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Zahraa Sedeeq Qasim
Department of Clinical Laboratory Sciences College of Pharmacy University of Mosul Mosul Iraq
2 shared publicationsFarah H. Omer
Clinical Laboratory Science Department, College of Pharmacy, Mosul University, Nineveh, Iraq
1 shared publication- Jean-Yves Maillard
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK
1 shared publication Karam A. Aldabbagh
Department of Clinical Laboratory Sciences College of Pharmacy University of Mosul Mosul Iraq
1 shared publication- Melanie Jay Wilson
School of Dentistry Cardiff University Cardiff Wales UK
1 shared publication - Rachel Jane Waddington
School of Dentistry, Cardiff University, Cardiff, UK
1 shared publication
Latest Publications
- Open Access
- 21 January 2026
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 38
Connotation of serum levels of vitamin D3 and LL-37 with urinary tract infection in type 2 diabetic patients
- 21 January 2026
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 38
Open AccessConnotation of serum levels of vitamin D3 and LL-37 with urinary tract infection in type 2 diabetic patients
- 11 January 2026
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 30 (1) , 246-262
Encountering the potentials of probiotics against urogenital tract infections in females
Urinary tract infection (UTI) and vaginitis are common conditions among females, significantly impacting overall life health and quality, imposing economical burdens and rising concerns of antibiotic resistance and limiting current treatments, probiotics have emerged as promising non antibiotic adjuvant and alternatives. Lactobacillus species restore and sustain a balanced microbiome offering protection against uro-pathogens by enhancement of epithelium barrier, immune modulation, competitive exclusions and biofilm disruptions. Clinical trials have documented the efficacy of probiotics both orally and vaginally in reducing UTI, preventing recurrences and restoring vaginal microbiota. This review highlights the aspects of probiotics mechanism of action, clinical trials and applications, exploring potentials of next generation probiotics and advancement in in delivery systems. While probiotics offer promising efficacy in managing UTI and vaginitis, further research studies are required to clarify exact mechanisms, strains potentials, dosage forms and doses, framing regulations regarding probiotics industry and tailored probiotics field.
- 11 January 2026
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 30 (1) , 246-262
Encountering the potentials of probiotics against urogenital tract infections in females
Urinary tract infection (UTI) and vaginitis are common conditions among females, significantly impacting overall life health and quality, imposing economical burdens and rising concerns of antibiotic resistance and limiting current treatments, probiotics have emerged as promising non antibiotic adjuvant and alternatives. Lactobacillus species restore and sustain a balanced microbiome offering protection against uro-pathogens by enhancement of epithelium barrier, immune modulation, competitive exclusions and biofilm disruptions. Clinical trials have documented the efficacy of probiotics both orally and vaginally in reducing UTI, preventing recurrences and restoring vaginal microbiota. This review highlights the aspects of probiotics mechanism of action, clinical trials and applications, exploring potentials of next generation probiotics and advancement in in delivery systems. While probiotics offer promising efficacy in managing UTI and vaginitis, further research studies are required to clarify exact mechanisms, strains potentials, dosage forms and doses, framing regulations regarding probiotics industry and tailored probiotics field.
- 19 March 2024
- Published by Egyptian Knowledge Bank in Microbes and Infectious Diseases
Pharmaceutical products microbial contamination; approaches of detection and avoidance
Pharmaceutical products’ microbial contamination is a serious worry in the pharmaceutical industry, as it can posture momentous health jeopardies to patients. Contamination with microbes can befall at any stage of manufacturing, starting with raw materials and ending with the finished products. It can also result from a variety of sources counting the environment, working personnel and equipment used. Common microorganisms that contaminate pharmaceutical products include bacteria, fungi, and viruses. The presence of these contaminants can compromise the quality, safety, and efficacy of pharmaceutical products, leading to product recalls, loss of reputation, and financial losses. Therefore, it is essential for pharmaceutical manufacturers to implement robust quality control measures to detect and prevent microbial contamination, including stringent cleaning and sanitation procedures, environmental monitoring, and microbiological testing. In this review, we discussed the main conventional and advanced technologies of detecting microbial contamination in pharmaceutical products. These techniques range from conventional culture methods to the more sophisticated technologies of gene sequencing and spectroscopy.
- 19 March 2024
- Published by Egyptian Knowledge Bank in Microbes and Infectious Diseases
Pharmaceutical products microbial contamination; approaches of detection and avoidance
Pharmaceutical products’ microbial contamination is a serious worry in the pharmaceutical industry, as it can posture momentous health jeopardies to patients. Contamination with microbes can befall at any stage of manufacturing, starting with raw materials and ending with the finished products. It can also result from a variety of sources counting the environment, working personnel and equipment used. Common microorganisms that contaminate pharmaceutical products include bacteria, fungi, and viruses. The presence of these contaminants can compromise the quality, safety, and efficacy of pharmaceutical products, leading to product recalls, loss of reputation, and financial losses. Therefore, it is essential for pharmaceutical manufacturers to implement robust quality control measures to detect and prevent microbial contamination, including stringent cleaning and sanitation procedures, environmental monitoring, and microbiological testing. In this review, we discussed the main conventional and advanced technologies of detecting microbial contamination in pharmaceutical products. These techniques range from conventional culture methods to the more sophisticated technologies of gene sequencing and spectroscopy.
- Open Access
- 8 March 2023
- Published by Pensoft Publishers in Pharmacia
- Vol. 70 (1) , 197-202
TAS2R38 gene in relation to Helicobacter pylori infection and blood groups in different age groups
Of the factors predisposing to gastric cancer is Helicobacter pylori infection affecting more than 50% of the general population. Genetic variation is an established player in certain diseases susceptibility. TAS2R38 gene polymorphisms have been found to influence bitter taste ability to chemicals with malicious characteristics and consequently affect metabolism and disease development. This study aimed to investigate the correlation between TAS2R38 gene polymorphisms and H. pylori seropositivity. The study involved 105 apparently healthy individuals. They were grouped into four groups according to their age and gender; young male, young female, middle-aged male and middle-aged female. All groups were tested for H. pylori serum antibody using screening rapid test. Participants were also tested for tasting PTC for TAS2R38 gene detection by using Bartovation PTC test paper and grouped accordingly into: homozygote (highly bitter taste), heterozygote (slight to moderate bitter taste), or negative gene carrier (no taste at all). ABO and Rhesus- blood grouping was determined by standard serological analysis. Of the 105 patients, 22.85% were tested homozygotes for TAS2R38 gene, 40.95% were heterozygotes and 36.19% were nontasters, no significant difference (p > 0.9). H. pylori seropositivity was encountered in 16.19% of the whole participants, 11.5% of the male participants and 20.75% of the female participants (p > 0.9). No significant difference in seropositivity was monitored among the four age groups (p > 0.3) and the ABO/Rh blood groups (p > 0.9). A lack of significant correlation (r = 0.046) between H. pylori antibody test positivity and tasting PTC (TAS2R38 gene) was reported. Similarly, no association was found between PTC tasting and participants’ ABO blood grouping, age or gender (r = 0.086, 0.083 and 0.029, respectively). Yet, weak negative (reverse) relationship (r = -0.29, p-value = 0.002) was gained between PTC and Rh grouping. No correlation was revealed between TAS2R38 polymorphism and the studied variable; age, gender and blood group indicating the absence of an apparent role of the gene in vulnerability to H. pylori infection. Further studies involving a larger sample size is required to confirm the obtained result.
- 8 March 2023
- Published by Pensoft Publishers in Pharmacia
- Vol. 70 (1) , 197-202
Open AccessTAS2R38 gene in relation to Helicobacter pylori infection and blood groups in different age groups
Of the factors predisposing to gastric cancer is Helicobacter pylori infection affecting more than 50% of the general population. Genetic variation is an established player in certain diseases susceptibility. TAS2R38 gene polymorphisms have been found to influence bitter taste ability to chemicals with malicious characteristics and consequently affect metabolism and disease development. This study aimed to investigate the correlation between TAS2R38 gene polymorphisms and H. pylori seropositivity. The study involved 105 apparently healthy individuals. They were grouped into four groups according to their age and gender; young male, young female, middle-aged male and middle-aged female. All groups were tested for H. pylori serum antibody using screening rapid test. Participants were also tested for tasting PTC for TAS2R38 gene detection by using Bartovation PTC test paper and grouped accordingly into: homozygote (highly bitter taste), heterozygote (slight to moderate bitter taste), or negative gene carrier (no taste at all). ABO and Rhesus- blood grouping was determined by standard serological analysis. Of the 105 patients, 22.85% were tested homozygotes for TAS2R38 gene, 40.95% were heterozygotes and 36.19% were nontasters, no significant difference (p > 0.9). H. pylori seropositivity was encountered in 16.19% of the whole participants, 11.5% of the male participants and 20.75% of the female participants (p > 0.9). No significant difference in seropositivity was monitored among the four age groups (p > 0.3) and the ABO/Rh blood groups (p > 0.9). A lack of significant correlation (r = 0.046) between H. pylori antibody test positivity and tasting PTC (TAS2R38 gene) was reported. Similarly, no association was found between PTC tasting and participants’ ABO blood grouping, age or gender (r = 0.086, 0.083 and 0.029, respectively). Yet, weak negative (reverse) relationship (r = -0.29, p-value = 0.002) was gained between PTC and Rh grouping. No correlation was revealed between TAS2R38 polymorphism and the studied variable; age, gender and blood group indicating the absence of an apparent role of the gene in vulnerability to H. pylori infection. Further studies involving a larger sample size is required to confirm the obtained result.
- Open Access
- 1 January 2023
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 27_special (27_special) , 1-3
BACTERIOTHERAPY
The vaccination in Albania : An assessment of the level of knowledge and behaviour of the population regarding vaccines.
- 1 January 2023
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 27_special (27_special) , 1-3
Open AccessBACTERIOTHERAPY
The vaccination in Albania : An assessment of the level of knowledge and behaviour of the population regarding vaccines.
- Open Access
- 31 December 2022
- Published by University of Mosul in Iraqi Journal of Pharmacy
- Vol. 19 (2) , 33-45
In vitro Assessment of the Antimicrobial Potential of Some Commercial Herbal Products
Natural plant products have been widely used as an alternative approach to treat microbial infections to overcome issues of antibiotics-associated side effects and the emergence of resistant pathogens. One of the most popular infections causing significant morbidity and death toll is urinary tract infection. This study is designed to evaluate the antimicrobial and antibiofilm potential of four commercial herbal products against five uropathogenic clinical isolates. In vitro, well diffusion assay and crystal violet staining techniques were used to evaluate the antimicrobial and antibiofilm effects respectively. Antimicrobial effect was reported for Renalka™ against Enterococcus faecium, ROWAtinex® against Staphylococcus aureus and E. faecium and UROCLEAR against Candida albicans. A significant antibiofilm effect, semi-quantified by stained biomass, was reported for all of the products included in the study against the tested pathogens but to a varying degree. Medicinal herbal products can exert a substantial prophylactic antibiofilm effect in addition to their beneficial health effects in treating urological pathologies.
- 31 December 2022
- Published by University of Mosul in Iraqi Journal of Pharmacy
- Vol. 19 (2) , 33-45
Open AccessIn vitro Assessment of the Antimicrobial Potential of Some Commercial Herbal Products
Natural plant products have been widely used as an alternative approach to treat microbial infections to overcome issues of antibiotics-associated side effects and the emergence of resistant pathogens. One of the most popular infections causing significant morbidity and death toll is urinary tract infection. This study is designed to evaluate the antimicrobial and antibiofilm potential of four commercial herbal products against five uropathogenic clinical isolates. In vitro, well diffusion assay and crystal violet staining techniques were used to evaluate the antimicrobial and antibiofilm effects respectively. Antimicrobial effect was reported for Renalka™ against Enterococcus faecium, ROWAtinex® against Staphylococcus aureus and E. faecium and UROCLEAR against Candida albicans. A significant antibiofilm effect, semi-quantified by stained biomass, was reported for all of the products included in the study against the tested pathogens but to a varying degree. Medicinal herbal products can exert a substantial prophylactic antibiofilm effect in addition to their beneficial health effects in treating urological pathologies.
- Open Access
- 3 November 2022
- Published by Wiley in European Journal of Oral Sciences
- Vol. 130 (6)
Determining the potential use of biosurfactants in preventing endodontic infections
Microbial biofilms play a dominant role in the failure of endodontic therapies. Bacterial adhesion is the first step in the establishment of biofilms, activating the host immune response leading to tissue damage. Biosurfactants are microbe‐derived tensioactive molecules with latent anti‐adhesive and anti‐microbial activity. This study reports the extraction and characterization of a biosurfactant from Lactobacillus (L.) plantarum (Lp‐BS) and investigates its anti‐microbial and anti‐adhesive properties compared to rhamnolipid, a commercially available biosurfactant. Lp‐BS, extracted from L. plantarum during the growth phase, was characterized as a glycoprotein, able to reduce surface tension and emulsify non‐polar liquids. Proteomic analysis of Lp‐BS identified three bacterial adhesin‐like proteins, suggesting roles in hindering bacterial adhesion. Lp‐BS did not show significant anti‐microbial activity against endodontic pathogens from the Streptococcus (Strep.) anginosus group or Enterococcus (Ent.) faecalis at 50 mg/ml. However, anti‐adhesive activity on abiotic surfaces was observed against both Strep. anginosus and Strep. intermedius. Rhamnolipid exhibited strong anti‐microbial activity, with minimum inhibitory concentrations of 0.097 mg/ml against Strep. anginosus, and 0.048 mg/ml against Strep. constellatus and Strep. intermedius, in addition to a marked anti‐adhesive activity. These findings offer preliminary evidence for the potential application of biosurfactants as an anti‐microbial and/or anti‐adhesive pharmacotherapy in endodontics.
- 3 November 2022
- Published by Wiley in European Journal of Oral Sciences
- Vol. 130 (6)
Open AccessDetermining the potential use of biosurfactants in preventing endodontic infections
Microbial biofilms play a dominant role in the failure of endodontic therapies. Bacterial adhesion is the first step in the establishment of biofilms, activating the host immune response leading to tissue damage. Biosurfactants are microbe‐derived tensioactive molecules with latent anti‐adhesive and anti‐microbial activity. This study reports the extraction and characterization of a biosurfactant from Lactobacillus (L.) plantarum (Lp‐BS) and investigates its anti‐microbial and anti‐adhesive properties compared to rhamnolipid, a commercially available biosurfactant. Lp‐BS, extracted from L. plantarum during the growth phase, was characterized as a glycoprotein, able to reduce surface tension and emulsify non‐polar liquids. Proteomic analysis of Lp‐BS identified three bacterial adhesin‐like proteins, suggesting roles in hindering bacterial adhesion. Lp‐BS did not show significant anti‐microbial activity against endodontic pathogens from the Streptococcus (Strep.) anginosus group or Enterococcus (Ent.) faecalis at 50 mg/ml. However, anti‐adhesive activity on abiotic surfaces was observed against both Strep. anginosus and Strep. intermedius. Rhamnolipid exhibited strong anti‐microbial activity, with minimum inhibitory concentrations of 0.097 mg/ml against Strep. anginosus, and 0.048 mg/ml against Strep. constellatus and Strep. intermedius, in addition to a marked anti‐adhesive activity. These findings offer preliminary evidence for the potential application of biosurfactants as an anti‐microbial and/or anti‐adhesive pharmacotherapy in endodontics.
- Open Access
- 11 January 2022
- Published by University of Mosul in Iraqi Journal of Pharmacy
- Vol. 18 (2) , 84-96
Bacteriophage as a Promising Alternative or Complementary Therapy to Antibiotics
The global issue of antibiotic resistance and the narrowing down of new antibiotic discoveries besides their cost has led to the reintroduction of bacteriophage as a focus of research projects. Phage therapy is mainly grounded on the discriminating ability of the bacteriophage to destroy the targeted bacterial cells, but not human cells, via lytic phages. Although there has been a number of life-sparing clinical trials and applications, this therapy is still facing challenging issues. This review gives an overview of the microbiology and history of the bacteriophages. It also reviews the past and current studies of phage therapy in humans and it’s commercial production. The aim of this study is to shed the light on the rapidly growing field of phage therapy and the obstacles that appear ahead as antimicrobial science moves away from broad dependence on conventional antibiotics.
- 11 January 2022
- Published by University of Mosul in Iraqi Journal of Pharmacy
- Vol. 18 (2) , 84-96
Open AccessBacteriophage as a Promising Alternative or Complementary Therapy to Antibiotics
The global issue of antibiotic resistance and the narrowing down of new antibiotic discoveries besides their cost has led to the reintroduction of bacteriophage as a focus of research projects. Phage therapy is mainly grounded on the discriminating ability of the bacteriophage to destroy the targeted bacterial cells, but not human cells, via lytic phages. Although there has been a number of life-sparing clinical trials and applications, this therapy is still facing challenging issues. This review gives an overview of the microbiology and history of the bacteriophages. It also reviews the past and current studies of phage therapy in humans and it’s commercial production. The aim of this study is to shed the light on the rapidly growing field of phage therapy and the obstacles that appear ahead as antimicrobial science moves away from broad dependence on conventional antibiotics.
- 1 January 2022
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 26(5) (26(5)) , 1342-1351
Assessment of Saccharomyces boulardii effect on rats Staphylococcus aureus induced skin infection: an in-vivo study
- 1 January 2022
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 26(5) (26(5)) , 1342-1351
Assessment of Saccharomyces boulardii effect on rats Staphylococcus aureus induced skin infection: an in-vivo study
- 1 January 2022
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 26(3) (26(3)) , 502-509
Evaluation of bacterial contents, package labelling and antimicrobial activity of some commercial probiotic products available in local market
- 1 January 2022
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 26(3) (26(3)) , 502-509
Evaluation of bacterial contents, package labelling and antimicrobial activity of some commercial probiotic products available in local market